FDA Approves Boston Scientific’s Deep Brain Stimulation Software
Company aims to utilize technology for efficient Parkinson’s treatment.
Boston Scientific Corporation has announced the FDA approval of its Vercise™ Neural Navigator 5 Software. According to the company, when this software is used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) systems, it will offer clinicians the data for programming in the treatment of people living with Parkinson’s disease or essential tremor.
"Developing meaningful tools to help physicians provide personalized treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions,” said Jim Cassidy, president, neuromodulation, Boston Scientific, in a company press release. “Providing effective DBS therapy is complex and can be time-consuming. This software will help streamline the process and allow for more doctor-patient interaction time."
Reference: Boston Scientific Receives FDA Approval for the Next Innovation in Image Guided Programming Software for Deep Brain Stimulation. Boston Scientific. July 11, 2023. Accessed July 18, 2023. https://news.bostonscientific.com/Boston-Scientific-Receives-FDA-ApprovNext-Innovation-Image-Guided-Programming-Software-Deep-Brain-Stimulation
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
